Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GEM103 + aflibercept
- Development stage
- Unknown
- Lead developer
- Disc Medicine
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravitreal
01
Overview
GEM103 + aflibercept is a combination therapy under clinical investigation for the treatment of neovascular age-related macular degeneration (nAMD) with or at risk for macular atrophy. GEM103 is a full-length recombinant human complement factor H (rCFH) protein designed to address complement hyperactivity and restore retinal health in genetically defined AMD patients. Aflibercept is an anti-vascular endothelial growth factor (anti-VEGF) agent that inhibits abnormal blood vessel growth in the retina. The combination aims to improve outcomes by targeting both the underlying genetic cause of disease progression and the vascular pathology[1][3][2].
- Other names
- GEM103 plus afliberceptGEM-103 plus afliberceptGEM 103 plus aflibercept
02
Targets
VEGFB (Vascular endothelial growth factor B)VEGFA (Vascular endothelial growth factor A)C3b (Complement Component 3b)PGF (Placental Growth Factor)
Beyond the preview
Go deeper on GEM103 + aflibercept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GEM103 + aflibercept.